Mode
Text Size
Log in / Sign up
Phase 4 N=96 Single-blind Diagnostic

The Feasibility of Florbetapir Quantitation

Alzheimers Disease

Enrolled (actual)
96
Serious AEs
Results posted
Jun 2015
Primary outcome: Primary: Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers) — 81.7; 88.8; 7.1 Percent Accuracy — p=0.0029

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Florbetapir F18 (Drug)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Avid Radiopharmaceuticals
Primary completion
Apr 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Total Accuracy (MIMNeuro Software, Low Accuracy Readers)
81.7; 88.8; 7.1 0.0029 sig
PRIMARY
Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm Low Accuracy Readers)
87.0; 91.8; 4.9 0.0025 sig
SECONDARY
Change in Total Accuracy (MIMNeuro Software, All Readers)
89.5; 93.8; 4.2
SECONDARY
Change in Reliability (MIMNeuro Software)
0.72; 0.79; 0.06; 0.73; 0.81; 0.08
SECONDARY
Change in Total Accuracy (Siemens Syngo.PET Software, Experimental Arm All Readers)
91.6; 93.9; 2.3
SECONDARY
Change in Reliability (Siemens Syngo.PET Software)
0.75; 0.82; 0.07; 0.76; 0.80; 0.04 0.0280 sig

Summary

The overall objective of the study is to assess the feasibility of implementing a quantitative process of florbetapir F 18 scan interpretation. The hypothesis is that the use of quantitative analysis will increase the accuracy of florbetapir F 18 scan interpretation.

Eligibility Criteria

Inclusion Criteria

  • Readers have undergone Amyvid reader training
  • Readers have minimal experience with quantitation of amyloid PET scans

Exclusion Criteria

  • Readers have previously been trained to quantitate amyloid PET scans
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01946243). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search